X-Brane Biosciences

Company

Also known as: Xbrane Biopharma

Related News

Multiple Lucentis Biosimilars Advance Through FDA: Two Approvals Secured, One Pending Review

Jun 05, 2026

Two new interchangeable Lucentis biosimilars — Lupin's Ranluspec and Formycon/Bioeq's Nufymco — have received FDA approval, while Xbrane's Lucamzi is under review with an October target date. The Lucentis global market was valued at $630 million in 2024.

Xbrane Biopharma Reports Full Year 2025 Results, FDA Issues CRL for Ranibizumab Biosimilar

Mar 03, 2026

Xbrane Biopharma reported full year 2025 revenue of SEK 152.4 million and a profit of SEK 127.2 million, driven by a SEK 168.9 million gain from the Alvotech transaction. The FDA issued a Complete Response Letter for the company's ranibizumab biosimilar application in October.